Evidence map›Paper›PMID 36715555›Full record

ArticleCancer science2023

Immune response elicited in the tumor microenvironment upon rMV-SLAMblind cancer virotherapy.

Kanako Moritoh, Koichiro Shoji, Yosuke Amagai, Tomoko Fujiyuki, Hiroki Sato, Misako Yoneda, Chieko Kai

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kanako MoritohLaboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Koichiro ShojiLaboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yosuke AmagaiLaboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Tomoko FujiyukiLaboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Hiroki SatoLaboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Misako YonedaLaboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Chieko KaiLaboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0001-9361-6362
Tokyo Medical University · JP

Funding

Health and Labour Sciences Research Grants 15ck0106001h0003Japan Agency for Medical Research and Development 19ck0106281h0003Japan Society for the Promotion of Science KAKENHI/JP21K07116
6 · The paper itself

Abstract

Oncolytic virotherapy is a promising therapy for cancer. We previously established a recombinant measles virus (rMV-SLAMblind) that targets NECTIN4-expressing cancer cells and demonstrated its antitumor effects using a xenograft model in an immunodeficient mouse. In the current study, to investigate the immune response after rMV-SLAMblind therapy, we developed an immunocompetent cancer mouse model by introducing the NECTIN4 gene into mouse cancer cell lines. NECTIN4-expressing mouse cancer cells were successfully killed by rMV-SLAMblind in vitro. After transplantation of the NECTIN4-expressing tumor cells, rMV-SLAMblind significantly suppressed tumor growth in immunocompetent mice. Thus, this immunocompetent mouse cancer model could be a powerful tool in which to study the effect of rMV-SLAMblind therapy on the immune response. Using this model we found that rMV-SLAMblind elicited significant activation of natural killer cells, type 1 helper T cells and the tumor-specific CD8

Indexed as

NeoplasmsOncolytic VirotherapyOncolytic VirusesAnimalsCell Adhesion MoleculesCell Line, TumorHumansImmunityMiceTumor MicroenvironmentCell Adhesion Moleculesantitumor immune responseimmunocompetent mouse modelNECTIN4oncolytic virotherapyrMV-SLAMblind

Identifiers

PMID36715555
PMCPMC10154881
OpenAlexW4318481808

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.